8-K: Health Catalyst Beats Q3 Guidance, Reiterates FY25 Outlook

Health Catalyst reported third-quarter 2025 financial results, exceeding revenue and Adjusted EBITDA guidance, while reaffirming its full-year 2025 outlook despite anticipated revenue headwinds in 2026.

Summary

• Total revenue for Q3 2025 was $76.3 million, exceeding the guidance of approximately $75.0 million.
• Technology revenue grew by 7% year-over-year to $52.1 million in Q3 2025.
• Adjusted EBITDA for Q3 2025 reached $12.0 million, surpassing the guidance of approximately $10.5 million, representing a 64% increase year-over-year.
• The company reported a net loss of $22.2 million for Q3 2025, which includes $6.9 million in non-recurring lease-related impairment charges and $4.8 million in restructuring costs.
• Full-year 2025 guidance was reiterated, expecting total revenue of approximately $310 million and Adjusted EBITDA of approximately $41 million.
• For Q4 2025, the company anticipates total revenue of approximately $73.5 million and Adjusted EBITDA of approximately $13.4 million.
• Early commentary for 2026 suggests revenue will be a few points lower than 2025, attributed to factors like a lower Dollar-Based Retention rate, fewer net new Platform Clients, Ignite migration headwinds, and the restructuring of less profitable TEMS relationships.
• The company expects improvement in Adjusted EBITDA in 2026 due to strategic focus, cost management, targeted investments, and migration optimization.
• Cash and cash equivalents decreased significantly from $249.645 million at December 31, 2024, to $40.305 million at September 30, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company exceeded its Q3 guidance for both revenue and Adjusted EBITDA, demonstrating strong operational performance in the quarter, the significant increase in net loss, substantial decrease in cash and cash equivalents, and a cautious revenue outlook for 2026 temper the overall positive sentiment. The strategic shift in migration approach is a positive for client relations but introduces near-term revenue headwinds.

Positives

• Q3 2025 total revenue of $76.3 million exceeded quarterly guidance of ~$75.0 million.
• Q3 2025 Adjusted EBITDA of $12.0 million surpassed quarterly guidance of ~$10.5 million, marking a 64% year-over-year increase.
• Gross profit increased by 8% year-over-year to $29.979 million, with gross margin improving from 36% to 39%.
• Adjusted Gross Profit increased by 11% year-over-year to $40.133 million, with Adjusted Gross Margin improving from 48% to 53%.
• Reiterated full-year 2025 guidance for both total revenue and Adjusted EBITDA, indicating confidence in meeting annual targets.
• Advancing Ignite migration efforts, remaining on schedule for roughly two-thirds of DOS clients to complete migration by the end of 2025.

Negatives

• Net loss for Q3 2025 significantly widened to $(22.229) million, a 51% increase from $(14.726) million in Q3 2024.
• Net loss per share, basic and diluted, increased to $(0.32) in Q3 2025 from $(0.24) in Q3 2024.
• Cash and cash equivalents decreased substantially from $249.645 million at December 31, 2024, to $40.305 million at September 30, 2025.
• Net cash used in operating activities for the nine months ended September 30, 2025, was $(9.181) million, compared to $18.086 million provided in the same period of 2024.
• Q4 2025 total revenue guidance of ~$73.5 million represents an anticipated 8% year-over-year decline.
• Early commentary for 2026 anticipates revenue to be a few points lower than 2025 due to lower Dollar-Based Retention, fewer net new Platform Clients, Ignite migration headwinds, and exiting less profitable relationships.
• The Q3 2025 net loss includes significant non-recurring charges: $6.9 million for lease-related impairment and $4.8 million for restructuring costs.

Risks

• Changes in laws and regulations applicable to the business model.
• Changes in market or industry conditions, regulatory environment, and receptivity to technology and services.
• Results of litigation or a security incident.
• The loss of one or more key clients or partners.
• Macroeconomic challenges, including high inflationary and/or high interest rate environments, tariffs, or market volatility and measures taken in response thereto, and natural disasters or new public health crises.
• Changes to abilities to recruit and retain qualified team members.

Future Outlook

For the fourth quarter of 2025, Health Catalyst expects total revenue of approximately $73.5 million and Adjusted EBITDA of approximately $13.4 million. The company reiterated its full-year 2025 guidance, projecting total revenue of approximately $310 million and Adjusted EBITDA of approximately $41 million. Looking ahead to 2026, revenue is anticipated to be a few points lower than 2025, influenced by factors such as a lower Dollar-Based Retention rate, a reduced number of net new Platform Clients, headwinds from Ignite migration, and the strategic exit or restructuring of less profitable TEMS relationships. Despite this, the company expects an improvement in Adjusted EBITDA in 2026, driven by ongoing efforts in strategic focus, cost management, targeted investments, and optimization of migrations.

Management Comments

• "I am pleased by our financial results, including total revenue of $76.3 million and Adjusted EBITDA of $12.0 million, with these results beating our quarterly guidance on each measure."
• "By focusing on high-impact solutions with proven ROI and maintaining a commitment to understanding and evolving with our clients, we have reaffirmed our full-year 2025 guidance."
• "We believe our commitment to strategic focus, cost management, and targeted investments positions us to drive sustained value for our clients and shareholders."
• "We believe our solutions are delivering measurable improvements where health systems need them the most – cost control and operational efficiency."
• "We have technology-first answers to health system problems even amid a dynamic macroenvironment."
• "We have adjusted our timeline and approach to be more client-centric, recognizing that some organizations prefer to remain on DOS for the near to medium term. We are committed to providing more flexibility and meeting clients where they are and we expect this approach will improve client experience and Dollar-Based Retention."

Industry Context

Health Catalyst operates in the dynamic healthcare data and analytics technology sector, which is increasingly focused on cost control and operational efficiency for health systems. The company's emphasis on 'technology-first answers' and 'high-impact solutions with proven ROI' aligns with the broader industry trend of leveraging data and AI to drive measurable clinical, financial, and operational improvements. The strategic adjustment to its Ignite migration timeline to be more client-centric reflects the need for flexibility and adaptability in a competitive market where client retention and satisfaction are paramount, especially amid a 'dynamic macroenvironment' that likely includes economic pressures on healthcare providers.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Positive Q3 performance against guidance and reiterated FY25 outlook may instill confidence, but the widening net loss, significant cash burn, and cautious 2026 revenue outlook could raise concerns about future profitability and growth.
• Employees: Restructuring costs mentioned in the financial notes indicate workforce reductions, which could impact employee morale and stability.
• Customers: The client-centric adjustment to the Ignite migration timeline is intended to improve client experience and Dollar-Based Retention, potentially leading to stronger long-term relationships.
• Creditors: The significant decrease in cash and cash equivalents and net cash used in operating activities, alongside debt repayment and issuance activities, will be closely monitored by creditors regarding liquidity and solvency.

Next Steps

• Host a conference call on November 10, 2025, at 5:00 p.m. E.T. to review the results.
• File the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025, on or about November 10, 2025.
• Continue advancing Ignite migration efforts, aiming for roughly two-thirds of DOS clients to complete migration by the end of 2025 and meaningful progress by the end of the first half of 2026.
• Focus on strategic initiatives, cost management, and targeted investments to drive sustained value and improve Adjusted EBITDA in 2026.

Key Dates

Recommendation

Health Catalyst delivered a mixed Q3 2025 performance, beating revenue and Adjusted EBITDA guidance, which is a positive signal for operational efficiency and management execution. However, the substantial increase in net loss, driven by non-recurring charges, and a significant reduction in cash and cash equivalents are notable concerns. The early 2026 outlook, projecting lower revenue due to various factors including migration headwinds and client retention, suggests a challenging near-term growth environment. While the company's strategic focus on cost management and client-centric migration is commendable for long-term stability, the immediate financial picture presents a balance of strengths and weaknesses. A 'hold' recommendation is appropriate as investors should monitor the execution of strategic initiatives, particularly the Ignite migration and cost management, to assess if the anticipated Adjusted EBITDA improvement in 2026 can offset the projected revenue decline and improve overall profitability and cash flow.

Keywords

Healthcare technology, Data analytics, Healthcare IT, Financial results, Earnings, Adjusted EBITDA, Revenue guidance, Ignite migration, Platform clients, HCAT